Vista Pharmaceuticals Ltd has announced a strategic joint venture partnership with Pleiades Therapeutics, marking a significant expansion in its global pharmaceutical development capabilities. The company informed BSE Limited about this development through a regulatory filing dated February 3, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Strategic Partnership Overview

The joint venture partnership establishes a collaborative framework for the end-to-end development of pharmaceutical products across two key segments:

Synergistic Business Model

The partnership is designed to leverage the complementary strengths of both organizations. Pleiades Therapeutics brings specialized R&D expertise to the collaboration, while Vista Pharmaceuticals contributes its robust manufacturing infrastructure and established marketing presence in strategic markets.

Key Strategic Elements

• R&D Integration: Combining Pleiades Therapeutics' research and development capabilities
• Manufacturing Leverage: Utilizing Vista Pharmaceuticals' established production facilities
• Market Access: Leveraging existing marketing presence in the United States and other key pharmaceutical markets
• Global Reach: Targeting both regulated markets and rest-of-the-world territories

Expected Business Impact

The collaboration is positioned to deliver multiple strategic benefits for both partner companies:

Regulatory Compliance

Vista Pharmaceuticals has fulfilled its disclosure obligations by informing BSE Limited of this material development. The company has also made the information available on its corporate website at www.vistapharmaceuticals.com , ensuring transparency for all stakeholders.

The announcement was signed by Dhananjaya Alli, Whole Time Director (DIN: 00610909), confirming the company's commitment to this strategic partnership. This joint venture represents Vista Pharmaceuticals' continued focus on expanding its pharmaceutical development capabilities and strengthening its position in the competitive global pharmaceutical market.

Vista Pharmaceuticals Limited, a pharmaceutical manufacturing company, has reported a wider net loss for the quarter ended June 30, 2025, amid declining revenue. The company also announced the reappointment of key executives and scheduled its Annual General Meeting.

Financial Performance

Vista Pharmaceuticals reported a net loss of Rs. 129.04 crore for the quarter ended June 30, 2025, compared to a loss of Rs. 85.70 crore in the same quarter last year. The company's revenue declined to Rs. 151.88 crore from Rs. 179.50 crore year-over-year, representing a 15.4% decrease.

The company's financial results for the quarter are summarized in the table below:

Corporate Updates

The Board of Directors of Vista Pharmaceuticals has approved several key corporate actions:

1. Reappointment of Directors: The board recommended the reappointment of two directors retiring by rotation - Mr. Umakanth Katta and Mr. Divakar Reddy Yerrabommanahalli.

2. Executive Reappointments: The company approved the reappointment of three key executives for three-year terms starting October 19, 2025, subject to shareholder approval:

   • Mr. Murali Meraga as Managing Director
   • Mr. Pavan Sathvik Gilaka as Whole-time Director
   • Mr. Dhananjaya Alli as Whole-time Director

3. Annual General Meeting: The 34th Annual General Meeting (AGM) is scheduled for September 30, 2025, to be conducted through video conferencing.

4. Book Closure: The Register of Members and Share Transfer Books will remain closed from September 24 to September 30, 2025 (both days inclusive).

Management Profiles

• Mr. Murali Meraga: Holds a B. Tech in Technology with extensive experience in Marketing, Administration, Finance, and Foreign Exchange management.
• Mr. Pavan Sathvik Gilaka: Possesses a Bachelor's degree in Business Administration (BBA) with professional experience in Human Resources, Marketing, and Administration.
• Dr. Dhananjaya Alli: A Promoter & Director of Vista Pharmaceuticals, holds a Ph.D. and M.S. in Pharmaceutical Sciences, playing a key role in the company's growth through research-driven strategies.

The company's Board of Directors has affirmed that none of the reappointed directors are debarred from holding office by any SEBI order or other authority.

Vista Pharmaceuticals continues to focus on its core business of manufacturing pharmaceutical products, as noted in its segment reporting.